TY - JOUR T1 - Cardiac events among patients with CV comorbidities: Pooled analysis of COPD trials comparing tiotropium with salmeterol JF - European Respiratory Journal JO - Eur Respir J VL - 42 IS - Suppl 57 SP - P754 AU - Kai-Michael Beeh AU - Klaus Rabe AU - Thomas Glaab AU - Diego Wyszynski AU - Inge Leimer AU - Norbert Metzdorf AU - Claus Vogelmeier AU - Leonardo Fabbri Y1 - 2013/09/01 UR - http://erj.ersjournals.com/content/42/Suppl_57/P754.abstract N2 - Background: Subgroup analyses of patients with concomitant cardiovascular (CV) diseases may help characterise safety profiles of COPD maintenance therapies.Aims and objectives: To compare the serious cardiac adverse event (SCAE) profiles, including fatalities, of patients with baseline CV conditions in a pooled analysis of 4 double-blind, randomized, parallel-group clinical trials of tiotropium HandiHaler® (HH) vs salmeterol metered dose inhaler (MDI).Methods: Incidence rates (IR): number of patients with event divided by 100 patient-years at risk. Rate ratios (RR) and 95% confidence intervals (CI): derived from Cochran-Mantel-Haenszel test stratified by study.Results: In total, 8836 patients were included. The IRs of SCAEs, and fatalities from cardiac diseases, during treatment by CV conditions at baseline are in the table.View this table:Conclusion: Tiotropium once daily via HH showed a comparable cardiac safety profile to salmeterol MDI in subgroups with CV conditions at baseline. ER -